Physician profile
Iona E Chapman
NPI 1720320385
$12,361.69
in general payments reported to CMS, 2019-2025
34 companies · $747 in 2025
The $747 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,141 · 2020: $1,036 · 2021: $2,279 · 2022: $2,755 · 2023: $2,460 · 2024: $943 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,971 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,970.95 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,168.01 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,733.70 | 2019-2025 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $1,702.80 | 2019-2025 | |
| Lilly USA, LLC | $858.62 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $736.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $722.76 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $648.36 | 2019-2025 | Nemluvio, Oracea, Epsolay |
| Incyte Corporation | $585.01 | 2021-2025 | Opzelura |
| Ucb, INC. | $510.38 | 2019-2025 | Cimzia, Bimzelx |
| Leo Pharma INC. | $404.51 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $364.37 | 2019-2025 | Ilumya |
| Pfizer INC. | $311.24 | 2019-2023 | |
| Amgen INC. | $298.82 | 2020-2024 | Otezla |
| Mayne Pharma Commercial LLC | $217.06 | 2019-2020 | |
| Hill Dermaceuticals, INC. | $192.05 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $136.64 | 2019-2025 | Cabtreo, Jublia |
| Dermavant Sciences, INC. | $110.42 | 2022-2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $93.84 | 2023-2024 | Zoryve |
| Almirall LLC | $75.67 | 2019-2020 | |
| Celgene Corporation | $71.44 | 2019 | |
| Epi Health, LLC | $64.57 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.09 | 2022-2023 | Sotyktu |
| Vyne Pharmaceuticals INC. | $53.51 | 2020-2021 | |
| Encore Dermatology INC. | $46.92 | 2019 | |
| Mylan Pharmaceuticals INC. | $33.11 | 2019 | |
| Dermira, INC. | $32.99 | 2020-2021 | |
| Journey Medical Corporation | $27.00 | 2022 | |
| Medtronic Vascular, INC. | $20.15 | 2020 | |
| Promius Pharma LLC | $19.86 | 2019 | |
| Kerecis Limited | $18.29 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.09 | 2024 | Spevigo |
| Mission Pharmacal Company | $14.42 | 2019 | |
| Merck Sharp & Dohme LLC | $10.82 | 2019 | |
| Organon LLC | $6.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iona Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.